Miltenyi Biotec Clinimacs Cd141 (Bdca-3) Gmp

Miltenyi Biotec The CD141 (BDCA-3) antigen is expressed at high levels on a minor subpopulation (about 0.02% of blood leukocytes) of human myeloid/conventional dendritic cells (cDCs). | CD141 (BDCA 3)-high blood cDCs are CD11c-dim, CD123–, CD4+, Lin–, CD45RO+, CD2–, and CD16– and express myeloid lineage markers. This population has been designated as type-1 cDCs (cDC1) and has distinct markers from the CD1c (BDCA-1)+ blood DCs population (designated cDC2). | Indeed, unlike CD1c (BDCA-1)+ cDC2, CD141 (BDCA-3)-high cDC1 lack expression of CD2 and Fc receptors such as CD32, CD64, or FcεRI. Furthermore, cDC1 differ from cDC2 in terms of Toll-like receptor expression. | CD141 (BDCA-3) is also present at very low levels on CD14+ monocytes, granulocytes, CD303 (BDCA 2)+ CD304 (BDCA-4/Neuropilin-1)+ plasmacytoid DCs and CD1c (BDCA-1)+ cDCs. CD141 is also known as thrombomodulin and mediates co-agglutination by interaction with thrombin and protein C, though nothing is known about its function on dendritic cells. | CD141+ cDCs are specialized in detection and uptake of necrotic cell debris of virally infected cells or tumor cells and cross-presentation of derived-antigens to CD8+ T cells. In addition they are able to secrete IFNλ, important in the development of an immune response. | The CliniMACS® CD141 (BDCA 1) Product Line consists of murine CD141 (BDCA 3) monoclonal antibodies conjugated to superparamagnetic iron dextran particles. One vial contains 7.5mL sterile, non pyrogenic solution. The performance of the CliniMACS CD141 (BDCA 3) Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative. Please inquire about required CliniMACS System components and accessories. | | - MLTY (Additional S&H or Hazmat Fees May Apply)